Parkside Financial Bank & Trust’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $150K | Sell |
194
-84
| -30% | -$64.3K | 0.01% | 540 |
|
|
2025
Q4 | $215K | Buy |
278
+115
| +71% | +$78.1K | 0.02% | 439 |
|
|
2025
Q3 | $91.7K | Buy |
163
+21
| +15% | +$11.9K | 0.01% | 701 |
|
|
2025
Q2 | $74.5K | Sell |
142
-44
| -24% | -$24.6K | 0.01% | 759 |
|
|
2025
Q1 | $118K | Sell |
186
-6
| -3% | -$4.13K | 0.02% | 524 |
|
|
2024
Q4 | $137K | Sell |
192
-3
| -2% | -$2.52K | 0.02% | 479 |
|
|
2024
Q3 | $205K | Buy |
195
+4
| +2% | +$4.45K | 0.03% | 360 |
|
|
2024
Q2 | $201K | Buy |
191
+2
| +1% | +$1.94K | 0.03% | 348 |
|
|
2024
Q1 | $182K | Buy |
189
+2
| +1% | +$1.9K | 0.03% | 371 |
|
|
2023
Q4 | $164K | Buy |
187
+25
| +15% | +$20.6K | 0.03% | 353 |
|
|
2023
Q3 | $133K | Buy |
162
+16
| +11% | +$12.6K | 0.03% | 339 |
|
|
2023
Q2 | $105K | Buy |
146
+8
| +6% | +$6.17K | 0.02% | 396 |
|
|
2023
Q1 | $113K | Buy |
138
+16
| +13% | +$12.1K | 0.03% | 358 |
|
|
2022
Q4 | $88K | Buy |
122
+17
| +16% | +$12.5K | 0.03% | 415 |
|
|
2022
Q3 | $73K | Buy |
105
+28
| +36% | +$17.6K | 0.02% | 413 |
|
|
2022
Q2 | $46K | Sell |
77
-19
| -20% | -$12.3K | 0.01% | 553 |
|
|
2022
Q1 | $67K | Buy |
96
+14
| +17% | +$8.86K | 0.02% | 450 |
|
|
2021
Q4 | $52K | Buy |
82
+9
| +12% | +$5.53K | 0.01% | 520 |
|
|
2021
Q3 | $44K | Buy |
73
+11
| +18% | +$6.83K | 0.01% | 532 |
|
|
2021
Q2 | $35K | Buy |
62
+12
| +24% | +$6.08K | 0.01% | 605 |
|
|
2021
Q1 | $24K | Sell |
50
-53
| -51% | -$25.8K | 0.01% | 713 |
|
|
2020
Q4 | $50K | Buy |
103
+46
| +81% | +$24.8K | 0.02% | 464 |
|
|
2020
Q3 | $32K | Buy |
57
+1
| +2% | +$606 | 0.01% | 521 |
|
|
2020
Q2 | $35K | Sell |
56
-6
| -10% | -$3.41K | 0.01% | 492 |
|
|
2020
Q1 | $30K | Buy |
62
+19
| +44% | +$7.84K | 0.01% | 472 |
|
|
2019
Q4 | $17K | Buy |
43
+20
| +87% | +$6.73K | 0.01% | 704 |
|
|
2019
Q3 | $6K | Buy |
23
+8
| +53% | +$2.37K | ﹤0.01% | 886 |
|
|
2019
Q2 | $5K | Sell |
15
-41
| -73% | -$13.7K | ﹤0.01% | 970 |
|
|
2019
Q1 | $23K | Buy |
56
+11
| +24% | +$4.53K | 0.01% | 562 |
|
|
2018
Q4 | $17K | Buy |
45
+30
| +200% | +$11K | 0.01% | 615 |
|
|
2018
Q3 | $6K | Buy |
15
+3
| +25% | +$1.14K | ﹤0.01% | 876 |
|
|
2018
Q2 | $4K | Sell |
12
-31
| -72% | -$9.7K | ﹤0.01% | 940 |
|
|
2018
Q1 | $15K | Buy |
43
+17
| +65% | +$5.91K | 0.01% | 634 |
|
|
2017
Q4 | $9K | Sell |
26
-3
| -10% | -$1.22K | ﹤0.01% | 765 |
|
|
2017
Q3 | $13K | Hold |
29
| – | – | 0.01% | 666 |
|
|
2017
Q2 | $14K | Buy |
29
+20
| +222% | +$8.75K | 0.01% | 648 |
|
|
2017
Q1 | $3K | Sell |
9
-214
| -96% | -$79.3K | ﹤0.01% | 915 |
|
|
2016
Q4 | $81K | Buy |
223
+1
| +0.5% | +$380 | 0.04% | 250 |
|
|
2016
Q3 | $89K | Buy |
222
+6
| +3% | +$2.41K | 0.04% | 253 |
|
|
2016
Q2 | $75K | Buy |
216
+201
| +1,340% | +$77.4K | 0.04% | 263 |
|
|
2016
Q1 | $5K | Buy |
15
+7
| +88% | +$2.88K | ﹤0.01% | 784 |
|
|
2015
Q4 | $5K | Buy |
8
+2
| +33% | +$1.08K | ﹤0.01% | 776 |
|
|
2015
Q3 | $2K | Buy |
+6
| New | +$3.22K | ﹤0.01% | 929 |
|
Other funds holding REGN
VCM
N
Parkside Financial Bank & Trust's REGN Position: Q1 2026 in Review
Parkside Financial Bank & Trust reduced its Regeneron Pharmaceuticals (REGN) stake by 30% in Q1 2026, selling an estimated $64.3K and leaving 194 shares worth $150K. The position accounts for 0.01% of the portfolio, ranked #540.
Parkside Financial Bank & Trust first reported a position in REGN in Q3 2015 and has held it in 43 quarters since. The position peaked at $215K in Q4 2025. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Parkside Financial Bank & Trust held 194 shares of Regeneron Pharmaceuticals worth $150K as of Q1 2026.
- Parkside Financial Bank & Trust sold 84 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $64.3K.
- Regeneron Pharmaceuticals made up 0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #540 holding.
- Parkside Financial Bank & Trust first reported a position in Regeneron Pharmaceuticals in Q3 2015 and has held it in 43 quarters since.
- Parkside Financial Bank & Trust's Regeneron Pharmaceuticals position peaked at $215K in Q4 2025.
- 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.